Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | ESRRG | P62508 | 3/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17345002 | 0.84 | TSHR (0.58) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL28852147 | 0.81 | IDO1 (0.53) | KMT2ATSHR | |
| SCHEMBL20850559 | 0.80 | ACP3 (0.44) | NR4A2RXRARXRBNR1H4HDAC3 | |
| SCHEMBL19116150 | 0.79 | PTPN2 (0.47) | NR4A2RXRARXRBESRRGESRRB | |
| SCHEMBL207268 | 0.79 | RAB9A (0.53) | NPC1RAB9AMAPTLMNATSHR | |
| SCHEMBL8384625 | 0.78 | TSHR (0.52) | MEN1KMT2ALMNATSHR | |
| SCHEMBL28365963 | 0.76 | TSHR (0.50) | TSHR | |
| SCHEMBL17746165 | 0.76 | TSHR (0.48) | NR4A2RXRARXRBESRRGESRRB | |
| SCHEMBL8389200 | 0.76 | NPC1 (0.53) | NPC1RAB9AANPEPERAP2MAPT | |
| SCHEMBL27599814 | 0.76 | TSHR (0.55) | NPC1RAB9AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-11136308-B2 | Substituted quinazoline and quinazolinone compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-11059819-B2 | Fused hetero-hetero bicyclic compounds and methods of use thereof | JANSSEN BIOTECH, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2020-02-27 | — | — | US | disclosed |
| US-20190345158-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-11-14 | — | — | US | disclosed |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-10280172-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-06-07 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | NR4A2 2119/4885RXRA 2107/4885RXRB 1333/4885 |
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | NR4A2 2189/4885RXRA 2254/4885RXRB 1439/4885 |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | NR4A2 3626/4885RXRA 2284/4885RXRB 1653/4885 |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | NR4A2 2189/4885RXRA 2254/4885RXRB 1439/4885 |
| US-11059819-B2 | Fused hetero-hetero bicyclic compounds and methods of use thereof | KRAS, NRAS, HRAS | NR4A2 2735/4885RXRA 2022/4885RXRB 1971/4885 |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | KRAS, NRAS, RB1 | NR4A2 894/4885RXRA 1671/4885RXRB 1241/4885 |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | KRAS, NRAS, HRAS | NR4A2 1674/4885RXRA 870/4885RXRB 965/4885 |
| US-20190345158-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NR4A2 2735/4885RXRA 2022/4885RXRB 1971/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NR4A2 4047/4885RXRA 4386/4885RXRB 3846/4885 |
| US-11136308-B2 | Substituted quinazoline and quinazolinone compounds and methods of use thereof | KRAS, NRAS, HRAS | NR4A2 2287/4885RXRA 2763/4885RXRB 2306/4885 |
| US-10280172-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | NR4A2 2119/4885RXRA 2107/4885RXRB 1333/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NR4A2 3602/4885RXRA 2320/4885RXRB 1675/4885 |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | NR4A2 1560/4885RXRA 3121/4885RXRB 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.